Pre-market hot trades in US stocks: POET Tech pre-market down 7.80%; Scinai Immunotherapeutics pre-market down 7.73%

Pre-market Hot Trades in US Stocks POET Tech is down 7.80% in pre-market trading. Based on recent key news: On April 27, POET Technologies had all orders canceled by Marvell for violating a confidentiality agreement, causing its stock price to plummet by 47.7%. Marvell accused POET of leaking purchase orders and shipping information, leading to a loss of market confidence, with the stock closing at $7.95. Source: Reuters On April 27, POET Technologies' stock price fell by 40.60% in pre-market trading, reflecting market concerns about its future prospects. Source: Benzinga On April 28, global energy and AI markets are turbulent, affecting investor confidence. Brent crude futures returned to $100 per barrel, and the AI industry faces legal challenges, requiring close attention to these factors' impact on the economy. Source: Wall Street Insight AI industry faces legal challenges, market volatility intensifies. Scinai Immunotherapeutics is down 7.73% in pre-market trading. Based on recent key news: On April 25, Scinai Immunotherapeutics announced a securities purchase agreement, leading to stock price fluctuations. The company plans to issue Series A and Series B warrants, with exercise prices of $0.48 and $0.55, respectively. This news attracted market attention, causing trading volume to surge, with the stock initially rising by 53.53% in pre-market but then retreating. On April 27, OSE Immunotherapeutics' partner Veloxis received FDA orphan drug designation for the prevention of heart transplant rejection. Although this news is not directly related to Scinai Immunotherapeutics, it may impact overall sentiment in the biotechnology industry. The biotechnology sector has been volatile recently, and policy changes should be monitored. Top Gainers in Pre-market US Stocks Direct Digital is up 45.22% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Calidi Biotherapeutics is up 39.24% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Profusa is up 28.36% in pre-market trading. There is no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. no_news